EMEA-001220-PIP03-16-M02

Table of contents

Key facts

Invented name
Olumiant
Active substance
baricitinib
Therapeutic area
Dermatology
Decision number
P/0311/2021
PIP number
EMEA-001220-PIP03-16-M02
Pharmaceutical form(s)
  • Oral suspension
  • Tablet
Condition(s) / indication(s)
Treatment of atopic dermatitis
Route(s) of administration
Oral use
Contact for public enquiries
Eli Lilly & Company Limited

E-mail: eu_paediatric@lilly.com 
Tel. +44 (0)1276 483000

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating